Dynamics of Rectal Balloon Implant Shrinkage in Prostate VMAT : Influence on Anorectal Dose and Late Rectal Complication Risk

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2017 Oct 18

PMID 29038832

Citations 13

Authors

Ben G L Vanneste

Y van Wijk

L C Lutgens

E J van Limbergen

E N van Lin

K van de Beek

P Lambin

A L Hoffmann

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the effect of a shrinking rectal balloon implant (RBI) on the anorectal dose and complication risk during the course of moderately hypofractionated prostate radiotherapy.

Methods: In 15 patients with localized prostate cancer, an RBI was implanted. A weekly kilovolt cone-beam computed tomography (CBCT) scan was acquired to measure the dynamics of RBI volume and prostate-rectum separation. The absolute anorectal volume encompassed by the 2 Gy equieffective 75 Gy isodose (V) was recalculated as well as the mean anorectal dose. The increase in estimated risk of grade 2-3 late rectal bleeding (LRB) between the start and end of treatment was predicted using nomograms. The observed acute and late toxicities were evaluated.

Results: A significant shrinkage of RBI volumes was observed, with an average volume of 70.4% of baseline at the end of the treatment. Although the prostate-rectum separation significantly decreased over time, it remained at least 1 cm. No significant increase in V of the anorectum was observed, except in one patient whose RBI had completely deflated in the third week of treatment. No correlation between mean anorectal dose and balloon deflation was found. The increase in predicted LRB risk was not significant, except in the one patient whose RBI completely deflated. The observed toxicities confirmed these findings.

Conclusions: Despite significant decrease in RBI volume the high-dose rectal volume and the predicted LRB risk were unaffected due to a persistent spacing between the prostate and the anterior rectal wall.

Citing Articles

Use of rectal balloon spacer in patients with localized prostate cancer receiving external beam radiotherapy.

Costa P, Vale J, Fonseca G, Costa A, Kos M Tech Innov Patient Support Radiat Oncol. 2024; 29:100237.

PMID: 38322778 PMC: 10846399. DOI: 10.1016/j.tipsro.2024.100237.

Assessment of Bioprotect's Biodegradable Balloon System as a Rectal Spacer in Radiotherapy: An Animal Study on Tissue Response and Biocompatibility.

Ramot Y, Levin-Harrus T, Ezratty A, Steiner M, Ezov N, Domb A Pharmaceutics. 2023; 15(12).

PMID: 38140085 PMC: 10747072. DOI: 10.3390/pharmaceutics15122744.

Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity.

Opbroek T, Cobussen A, Van Limbergen E, Vanneste B J Contemp Brachytherapy. 2023; 15(2):154-158.

PMID: 37215617 PMC: 10196732. DOI: 10.5114/jcb.2023.126051.

Is an Endorectal Balloon Beneficial for Rectal Sparing after Spacer Implantation in Prostate Cancer Patients Treated with Hypofractionated Intensity-Modulated Proton Beam Therapy? A Dosimetric and Radiobiological Comparison Study.

Ahmad Khalil D, Wulff J, Jazmati D, Geismar D, Baumer C, Kramer P Curr Oncol. 2023; 30(1):758-768.

PMID: 36661707 PMC: 9857887. DOI: 10.3390/curroncol30010058.

Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study.

Bjoreland U, Notstam K, Fransson P, Soderkvist K, Beckman L, Jonsson J Radiat Oncol. 2023; 18(1):1.

PMID: 36593460 PMC: 9809044. DOI: 10.1186/s13014-022-02197-x.

References

Vanneste B, van de Beek K, Lutgens L, Lambin P . Implantation of a biodegradable rectum balloon implant: tips, Tricks and Pitfalls. Int Braz J Urol. 2017; 43(6):1033-1042. PMC: 5734065. DOI: 10.1590/S1677-5538.IBJU.2016.0494. View

Pinkawa M, Berneking V, Konig L, Frank D, Bretgeld M, Eble M . Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. Strahlenther Onkol. 2016; 193(1):22-28. DOI: 10.1007/s00066-016-1040-6. View

Kupelian P, Willoughby T, Reddy C, Klein E, Mahadevan A . Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007; 68(5):1424-30. DOI: 10.1016/j.ijrobp.2007.01.067. View

Song D, Herfarth K, Uhl M, Eble M, Pinkawa M, van Triest B . A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys. 2013; 87(1):81-7. PMC: 3737267. DOI: 10.1016/j.ijrobp.2012.12.019. View

Noyes W, Hosford C, Schultz S . Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 82(5):1918-22. DOI: 10.1016/j.ijrobp.2011.02.034. View

Al-Mamgani A, van Putten W, Heemsbergen W, van Leenders G, Slot A, Dielwart M . Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(4):980-8. DOI: 10.1016/j.ijrobp.2008.02.073. View

Valdagni R, Kattan M, Rancati T, Yu C, Vavassori V, Fellin G . Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys. 2011; 82(5):1957-66. DOI: 10.1016/j.ijrobp.2011.03.028. View

Denham J, Steigler A, Tai K, Joseph D, Matthews J, Atkinson C . Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiother Oncol. 2013; 107(2):123-8. DOI: 10.1016/j.radonc.2013.03.025. View

Pinkawa M, Corral N, Caffaro M, Piroth M, Holy R, Djukic V . Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2011; 100(3):436-41. DOI: 10.1016/j.radonc.2011.09.005. View

10.

Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D . Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015; 92(5):971-977. DOI: 10.1016/j.ijrobp.2015.04.030. View

11.

Huang T, Chou K, Yang S, Chang C, Liang J, Zhang G . Fractionated changes in prostate cancer radiotherapy using cone-beam computed tomography. Med Dosim. 2015; 40(3):222-5. DOI: 10.1016/j.meddos.2014.12.003. View

12.

Wolf F, Gaisberger C, Ziegler I, Krenn E, Scherer P, Hruby S . Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol. 2015; 116(2):221-5. DOI: 10.1016/j.radonc.2015.07.027. View

13.

Zelefsky M, Levin E, Hunt M, Yamada Y, Shippy A, Jackson A . Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(4):1124-9. DOI: 10.1016/j.ijrobp.2007.11.044. View

14.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn P . Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015; 16(3):274-83. DOI: 10.1016/S1470-2045(14)70482-6. View

15.

Fonteyne V, Ost P, Vanpachtenbeke F, Colman R, Sadeghi S, Villeirs G . Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?. Radiother Oncol. 2014; 113(3):398-403. DOI: 10.1016/j.radonc.2014.10.014. View

16.

Vanneste B, Van De Voorde L, de Ridder R, Van Limbergen E, Lambin P, van Lin E . Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis. 2015; 30(10):1293-303. PMC: 4575375. DOI: 10.1007/s00384-015-2289-4. View

17.

Chen Z, Yang Z, Wang J, Hu W . Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy. Radiat Oncol. 2016; 11:103. PMC: 4969718. DOI: 10.1186/s13014-016-0681-z. View

18.

Melchert C, Gez E, Bohlen G, Scarzello G, Koziol I, Anscher M . Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol. 2013; 106(2):210-4. DOI: 10.1016/j.radonc.2013.01.007. View

19.

Kuban D, Tucker S, Dong L, Starkschall G, Huang E, Cheung M . Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 70(1):67-74. DOI: 10.1016/j.ijrobp.2007.06.054. View

20.

Strom T, Wilder R, Fernandez D, Mellon E, Saini A, Hunt D . A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014; 111(1):126-31. DOI: 10.1016/j.radonc.2014.02.011. View